Why the study?
Data on pacemaker insertion complicating TAVR in women are scarce.
Does permanent pacemaker insertion following TAVR impact 1-year VARC-2 efficacy and safety endpoints in women?
Does permanent pacemaker insertion following TAVR impact 1-year VARC-2 efficacy and safety endpoints in women?
In women undergoing TAVR, permanent pacemaker insertion is frequent, predicted by pre-existing RBBB and valve type, and prolongs hospital stay without significantly affecting 1-year outcomes.
Reassures that PPI does not worsen 1-year outcomes in women post-TAVR; leaves open optimal strategies to minimize post-procedure stay.
OBJECTIVES: To describe the incidence, predictors, and clinical impact of permanent pacemaker insertion (PPI) following transcatheter aortic valve replacement (TAVR) in women. BACKGROUND: Data on pacemaker insertion complicating TAVR in women are scarce. METHODS: The Women's International Transcatheter Aortic Valve implantation (WIN-TAVI) is a prospective registry evaluating the safety and efficacy of TAVR in women. We included patients without preprocedural pacemakers and divided them into two groups: (1) PPI and (2) no-PPI. We identified PPI predictors using logistic regression and studied its clinical impact on the Valve Academic Research Consortium (VARC)-2 efficacy and safety endpoints. RESULTS: HR 1.22, 95% CI 0.83-1.79, p = 0.31, respectively). CONCLUSION: Pacemaker implantation following TAVR is frequent among women and is associated with pre-existing RBBB and valve type. PPI prolongs hospital stay, albeit without any significant impact on 1-year outcomes.
No takes yet. Share an insight, caveat, or question.
Nicolas et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: